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In Parkinson’s disease (PD), midbrain dopaminergic neuronal death is linked to the accumulation of aggregated α-synuclein. The
familial PD mutant form of α-synuclein, E46K, has not been thoroughly evaluated yet in an organismal model system. Here,
we report that E46K resembled wild-type (WT) α-synuclein in Saccharomyces cerevisiae in that it predominantly localized to the
plasma membrane, and it did not induce signiﬁcant toxicity or accumulation. In contrast, in Schizosaccharomyces pombe, E46K
did not associate with the plasma membrane. Instead, in one strain, it extensively aggregated in the cytoplasm and was as toxic
as WT. Remarkably, in another strain, E46K extensively associated with the endomembrane system and was more toxic than WT.
Our studies recapitulate and extend aggregation and phospholipid membrane association properties of E46K previously observed
in vitro and cell culture. Furthermore, it supports the notion that E46K generates toxicity partly due to increased association with
endomembrane systems within cells.
1.Introduction
Parkinson’s disease (PD)isafatalandincurableneurodegen-
erative disorder characterized by resting tremors, postural
instability, and bradykinesia [1]. The death of midbrain
substantia nigra neurons characterizes the pathology of both
familial and sporadic forms of PD. Two types of molecules
accumulate within these dying cells: misfolded and aggre-
gatedα-synucleinincytoplasmicinclusionscalledLewybod-
ies [2] and oxidative free radicals [1, 3]. Therefore, a major
hypothesis is that α-synuclein misfolding and aggregation is
linked to neuronal toxicity in PD [4–6]. While the molecular
basis of sporadic PD is still unclear, mutations in six genes
cause familial PD [7], including three point mutations
(A53T, A30P, and E46K) within the α-synuclein gene [8–10].
In addition to self-aggregation [11–13], several other α-
synuclein properties that may be relevant to PD include
maintenance of neurotransmitter vesicular pools [14, 15],
synaptic plasticity [16, 17], phospholipid binding and lipid
metabolism [18–21], microtubule binding [22], chaperone-
like ability [23–25] ,a n dE R - G o l g it r a ﬃcking [26, 27]. While
the A30P and A53T familial mutants are widely studied in
how they alter the above properties to cause cytotoxicity and
contribute to PD pathogenesis [28], less is known about the
third and most recently discovered familial mutant, E46K.
Thus far, E46K is known to aggregate into ﬁbrils more
rapidly than wild-type α-synuclein in vitro [29, 30] and in
cell culture [31]. Additionally, recent biochemical studies
suggest that E46K enhances contact between the amino
and carboxyl domains although whether this interaction
increases the likelihood of aggregation is still being sorted
[32]. In contrast to the A30P and A53T familial mutants,
E46K exhibits a reduced accumulation of early oligomers
[13, 33, 34]. Like wild-type α-synuclein, E46K can form ion
channel-likeporesinlipidbilayers[34]althoughrecentwork
suggests that these channels are less conductive than those
formed by wild-type α-synuclein [35]. On the other hand,
E46K binds phospholipids more readily than wild-type α-
synuclein [29, 36, 37] and is more potent in inducing toxicity
in neuroblastoma cells that are cotreated with cytokines
[38]. In living cells, however, little is still known of E46K’s
ability to bind either the plasma membrane or internal2 ISRN Neurology
membrane systems. Nor is it clear how E46K aggregation
and/or membrane association might cause cellular toxicity.
Budding and ﬁssion yeast models have advanced our
molecular understanding of several neurodegenerative dis-
eases, including PD [21, 39–42]. Yeasts revealed that α-
synuclein binds plasma membranes extensively in addition
to its propensity to aggregate, but the relative importance
of aggregation and membrane binding to toxicity is still
unresolved [21, 43–46]. Yeasts have also provided evidence
that conditions for α-synuclein toxicity can be varied.
Some models demonstrate α-synuclein expression and dose-
dependent aggregation itself causes toxicity [21, 44], while
others report that α-synuclein-dependent toxicity, especially
when moderately expressed, requires additional factors, such
as proteasomal inhibition and oxidative stress [43, 45], or
tau coexpression [43]. In 2003, Willingham et al. identiﬁed
eighty-six yeast genes that were synthetically lethal with α-
synuclein[47].Similarly,disruption ofthesecretorypathway
[44] and ER-Golgi traﬃcking [26, 27] were ﬁrst found in
yeast to increase α-synuclein toxicity.
Here, we exploited the utility of both budding yeast and
ﬁssion yeasts to test the hypothesis that the E46K mutant
aggregates and binds membranes more strongly than WT
α-synuclein in living organisms and that it accumulates to
induce cellular toxicity. Indeed, we found that E46K binds
the plasma membrane in budding yeast and associates with
endomembrane systems and form intracellular aggregations
in ﬁssion yeast. While E46K is not toxic to budding yeast,
it is toxic to ﬁssion yeast especially when associated with
internal membrane systems. This E46K-enhanced toxicity is
best correlated with reduced cellular growth.
2. Results
As described in our past studies [45, 46], we tagged α-
synuclein with GFP at its C-terminus and induced its
expression with galactose in budding yeast and by removal
of thiamine (the repressor) in ﬁssion yeast.
2.1. E46K Is Selectively Toxic in Fission Yeast but Not in
Budding Yeast. Our ﬁrst goal was to assess whether E46K
was toxic to budding and ﬁssion yeasts, and we report that
E46K is toxic to yeasts, albeit in a species- and strain-speciﬁc
manner.
First, for budding yeast, we examined two haploid strains
of opposite mating types (BY4741 mat a and BY4742 mat α)
and a diploid strain (BY4743 mat a/α). E46K was not toxic to
any strain, as assessed by two assays: serial dilution spotting
on solid growth plates (Figure 1(a); BY4742 not shown) and
growth curves from liquid culture (data not shown). BY4741
cells that expressed E46K grew equally well as cells that did
not express α-synuclein (vector alone and GFP) and those
that expressed WT α-synuclein or two other familial mutants
(A30P and A53T; Figure 1(a), top). Therefore, as we had
previously reported for WT, A30P, and A53T [45], E46K
α-synuclein did not adversely aﬀect budding yeast growth.
Additionally, neither the mating type (data not shown) nor
ploidy doubling (Figure 1(a), bottom) altered the lack of
E46K α-synuclein-dependent toxicity in buddingyeast.
BY4741 (MAT a)
Repressed Induced
Vector
GFP
WT
E46K
A30P
A53T
Repressed Induced
Vector
GFP
WT
E46K
A30P
A53T
BY4743 (MAT a/α)
(a) Budding Yeast
Repressed Induced
Vector
GFP
WT
E46K
A30P
A53T
Repressed Induced
Vector
GFP
WT
E46K
A30P
A53T
SP3 (h+)
TCP1 (h−)
(b) Fission Yeast
Figure 1: E46K exhibits species- and strain-speciﬁc toxicity in yeasts. (a)
LEFT—BY4741 (mat a) and BY4743 (diploid mat a/α) budding yeast cells
expressing WT, E46K, A30P, or A53T α-synuclein were serially diluted 5-
fold and spotted onto repressing (glucose) or inducing (galactose) plates
and grown for two days. Vector alone and GFP served as controls. No
E46K-dependent α-synuclein toxicity was observed in either strain. (b)
LEFT—TCP1 and SP3 ﬁssion yeast cells expressing WT, E46K, A30P, or
A53T α-synuclein were serially diluted 5-fold and spotted onto repressing
(+thiamine) or inducing (−thiamine) plates. Similar to budding yeast,
vector alone and GFP served as controls. In both strains, WT, E46K, and
A53T were toxic, but not A30P. In SP3, E46K was more toxic than WT.ISRN Neurology 3
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Figure 2: E46K associates with the plasma membrane in budding yeast. (a) Live cell GFP microscopy of BY4741 cells expressing WT, E46K,
A30P,orA53Tα-synucleinandGFPaloneat24and48hoursofexpression(left).Quantiﬁcation: ∼750cellsofeachtypeweresc oredforthese
localization patterns: cytoplasmically diﬀuse, plasma membrane, aggregate, plasma membrane/diﬀuse, and plasma membrane/aggregate
(right). Phenotypes were plotted as a percent of total cells that ﬂuoresced. (b) BY4742 and (c) BY4743 cells expressing WT, E46K, A30P, or
A53T α-synuclein at 24 and 48 hours of expression. In each of these three strains, E46K consistently localized to the plasma membrane just
like WT and A53T, while A30P and GFP alone were predominantly cytoplasmically diﬀuse.
Next, we examined how α-synuclein aﬀected the growth
of two haploid ﬁssion yeast strains of opposite mating types:
h− (TCP1) and h+ (SP3). In contrast to our budding yeast
ﬁndings, we found that several α-synuclein variants were
toxic to ﬁssion yeast (Figure 1(b)). Firstly, when compared to
vector alone and GFP expressing cells, WT, E46K and A53T
α-synuclein expressing cells were each toxic in both strains,
but not A30P (Figure 1(b)). In TCP1, E46K and WT were
toxic to similar extents but less than A53T (Figure 1(b), top).
However, the strength of E46K toxicity was strikingly strain-
speciﬁc. In SP3, E46K was more toxic than WT yet still less
than A53T (Figure 1(b), bottom).
2.2. E46K Localizes to the Plasma Membrane in Budding Yeast.
To gain insight into E46K α-synuclein’s diﬀerential toxicity
in yeasts, we asked where it localized within the cells. Using
live cell GFP imaging, we ﬁrst tracked its localization in
budding yeast. E46K α-synuclein consistently localized to
the plasma membrane of BY4741 yeast during 48 hours of
expression, similar to WT and A53T α-synuclein localization
patterns (Figure 2(a)) that we previously had reported for
BY4741 [45]. Quantiﬁcation of localization in ﬂuorescing
cells indicates that more than 90% expressed E46K α-
synuclein at the plasma membrane (Figure 2(a)). Unlike
A53T, however, E46K α-synuclein was rarely seen aggregated4 ISRN Neurology
in the cytoplasm (Figure 2(a)). Nor did we observe any E46K
localization to internal endomembrane systems. In contrast,
A30P α-synuclein was mostly cytoplasmically diﬀuse, similar
to GFP alone (Figure 2(a)) [45].
E46K plasma membrane association and the patterns of
localization of the other α-synuclein variants were main-
tained in BY4742 (Figure 2(b)) and BY4743 (Figure 2(c))
strains. We next wondered if E46K bound the plasma
membrane more extensively than WT α-synuclein but found
no diﬀerence in the extent of plasma membrane association
between them over the ﬁrst 24 hours of expression: both
appeared at the plasma membrane as early as 6 hours to
similar extents (Figure 2(d)).
Thus, the lack of E46K α-synuclein toxicity in budding
yeasts correlated with plasma membrane association.
2.3. E46K Aggregates and Associates with the Endomembrane
System in Fission Yeast. In stark contrast to budding yeast,
E46K α-synuclein was prominently absent at the plasma
membrane when examined in the two haploid ﬁssion yeast
strains (Figure 3). In TCP1, E46K aggregated in the cyto-
plasm, again strikingly similar to WT and A53T α-synuclein
(Figure 3(a)) that we previously had reported in TCP1 [46].
A30P α-synuclein and GFP alone were cytoplasmically dif-
fuse(Figure 3(a)),alsoaspreviouslyreported[46].Mostcells
had 1–3 aggregates, but some had up as many as 5–10 per
cell (Figure 3(c)). These aggregates were outside the nucleus,
as determined by DAPI staining (Figure 3(d), top). Notably,
DAPI staining typically altered the pattern of α-synuclein
localization, reducing the size and location of α-synuclein
puncta,whichsuggeststhatsomeofthelargeraccumulations
were either a collection of dispersible smaller aggregates or
compact membranous vesicles (Figure 3(d), top).
However, in the second strain SP3, E46K localization was
strikingly diﬀerent. Initially, up to 24 hours of expression,
bothE46KandWTα-synucleindistributedtothemembrane
linings of many intracellular compartments, in addition to
aggregating in the cytoplasm (Figure 3(b)). Over the next
24 hours, 76% WT α-synuclein expressing cells contained
aggregates similar to TCP1, while E46K α-synuclein was
even more prominently localized to diverse intracellular
locations (98% cells),withno cellscontaining just aggregates
(Figure 3(b)). Over this same course of time, A30P α-
synuclein remained cytoplasmically diﬀuse while, A53T was
mostly aggregated by 48 hours (84%), with endomembrane
localization less extensive than E46K (16%; Figure 3(b)).
This E46K intracellular localization pattern excluded the
nucleus but not the nuclear envelope (Figure 3(d), lower),
andprominentlylitupperinuclearandvacuolar/prevacuolar
compartments (Figure 3(b)), and other components of the
endomembrane system that need further identiﬁcation.
Often, vesicular accumulations were observed within cells:
mostly with E46K, less with WT, and rarely with A53T
(Figure 3(e)).
Thus, the added toxicity of E46K α-synuclein in SP3
ﬁssion yeast appears correlated best with its localization to
diverse endomembrane organelles.
2.4. E46K Localization in Fission Yeast Is Concentration
Dependent. We previously reported that WT and A53T
α-synuclein aggregate in a time- and concentration-
dependent manner in ﬁssion yeast, providing live cell
support for the nucleation polymerization hypothesis [46].
Whether E46K does the same has not been reported. Indeed,
we found that E46K α-synuclein localization in TCP1 was
time-dependent (Figure 4(a)). Over a time course of 48
hours, E46K was initially diﬀuse in the cytoplasm for the
ﬁrst 12 hours, but thereafter aggregated into one or more
punctate aggregates within individual cells (Figure 4(a)). By
18 hours, less than 5% cells had cytoplasmically diﬀuse E46K
while, WT α-synuclein was cytoplasmically diﬀuse in 10%
cells even at 30 hours (Figure 4(a)).
Importantly, the E46K pattern of aggregation closely
resembled A53T α-synuclein aggregation (Figure 4(a)).
Remarkably, at no point over the time course was E46K
α-synuclein (nor WT or A53T) localized at the plasma
membrane (Figure 3(a)). A30P α-synuclein remained cyto-
plasmically diﬀuse and never aggregated over this same time
course (data not shown). Similarly, E46K α-synuclein also
aggregated in TCP1 in a concentration dependent manner,
which was demonstrated by growing E46K cells in the
presence of decreasing amounts of the repressor, thiamine
(10, 1.0, 0.1, and 0μM; Figure 4(b), left). At the two highest
thiamine concentrations, E46K α-synuclein was diﬀusely
localized in the cytoplasm (Figure 4(b), left). However, at the
lower thiamine concentrations as more protein is expressed,
E46K started aggregating in most cells, similar to WT and
A53T α-synuclein (Figure 4(b), left) .T h el o wl e v e lo fα-
synuclein observed by GFP ﬂuorescence even at the highest
thiamine concentration was conﬁrmed by Western blotting
(Figure 4(c), right).
Thus, E46K α- s y n u c l e i na g g r e g a t e di nat i m e -a n d
concentration-dependent manner, supporting the nucle-
ation polymerization model. Alternatively, the data can
also be explained by concentration-dependent membrane
localization as well, if the E46K puncta are, in fact, compact
membrane structures, rather than aggregates.
2.5. E46K Modestly Accumulates in Fission Yeast and Is
Phosphorylated in Both Yeasts. We wondered if the strain-
speciﬁc enhancement of E46K α-synuclein toxicity in ﬁssion
yeast that was lacking in budding yeast was partly due
to its selective accumulation in ﬁssion yeast. In budding
yeast, E46K and WT α-synuclein were indeed either similar
(BY4741) or even lower (BY4743) at 24 and 48 hours of
expression, indicating a lack of accumulation (Figure 5(a)).
In ﬁssion yeast, however, we did observe a slight increase in
E46K α-synuclein expression relative to WT in both TCP1
(48hrs) and SP3 strains (both 24 and 48hrs; Figure 5(b)).
Thus, E46K α-synuclein toxicity may be linked to this
modest accumulation.
Given that serine phosphorylation is linked to α-
synuclein related PD pathology [48–50], we next asked if
E46K toxicity is linked to phosphorylation. Firstly, we found
that both E46K and WT α-synuclein were phosphorylated
at serine-129 in both budding and ﬁssion yeasts and to the
same extent (Figure 5(c)). Importantly, the enhanced E46K
toxicity in SP3 was not correlated with altered level of α-
synuclein phosphorylation (Figure 5(c)).ISRN Neurology 5
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Figure 3: E46K α-synuclein exhibits strain-speciﬁc aggregation and endomembrane localization in ﬁssion yeast. (a and b) Live cell
GFP microscopy of TCP1 cells (a) and SP3 cells (b) expressing WT, E46K, A30P, or A53T α-synuclein, and GFP alone, at 24 and 48
hours of expression (left). Quantiﬁcation: ∼750 cells of each type were scored for these localization patterns: cytoplasmically diﬀuse,
aggregate, endomembrane, endomembrane/diﬀuse, endomembrane/aggregate (right). Phenotypes were plotted as a percent of total cells
that ﬂuoresced (N = 2). In TCP1, E46K α-synuclein mostly aggregated in TCP1, like WT and A53T. In SP3, E46K α-synuclein became
prominenty localized to endomembrane systems, more so than WT and A53T. A30P was cytoplasmically diﬀuse like GFP in both strains.
(c) E46K aggregates mostly varied from 1–5 per cell, but as many as 10 aggregates per cell were observed. (d) DAPI staining indicated that
E46K localization in both strains (TCP1: top; SP3: bottom) was outside the nucleus. (e) E46K cells often exhibited prevacuolar localization
and vesicular accumulation.
2.6. E46K Exhibits Reduced Growth and Survival in Fission
Yeast. Finally, we asked if the selective E46K α-synuclein
toxicity in ﬁssion yeast was linked to a reduction in
organismal growth and survival. As shown in the schematic
(Figure 6(a)), 1000 yeast cells each expressing WT or E46K
α-synuclein or containing parent vector alone for either 8
(early log phase of growth) or 18 hours (late log phase) were
plated onto repressing or inducing media. These survival
plates were then ﬁrst grown for two days, and the induced
plates were grown even further for three more days.
Firstly, in the TCP1 strain both E46K and WT α-
synuclein expressing cells were signiﬁcantly reduced in
colony size compared to parent vector cells when they
continued to express α-synuclein (induction= Figure 6(b)),
but not when they stopped expressing α-synuclein (repres-
sion—Figure 6(b)). This was true irrespective of whether α-
synucleinexpressingcellswereplatedfromeitherearlyorlate
log phase of growth. Three days later, both WT and E46K α-
synuclein cells did gain the original colony sizes initially seen
with parent vector cells (Figure 6(b)). We did not observe6 ISRN Neurology
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Figure 4: E46K α-synuclein aggregates in a time- and concentration-dependent manner in ﬁssion yeast. (a) Time course: Left—TCP1
cells expressing WT, A53T, or E46K α-synuclein (grown on media without thiamine) visualized using a ﬂuorescent microscope over a
48-hour time period. Right—Quantiﬁcation of the number of α-synuclein aggregates in each cell plotted as a percent of total cells that
ﬂuoresced (N = 2). E46K and A53T α-synuclein aggregated more intensely and quickly than WT. (b) Concentration: Left—TCP1 cells
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increasing expression of α-synuclein and cells were visualized using a ﬂuorescent microscope at 24 hours. Right—Quantiﬁcation of number
of aggregates in each cell plotted as a percent of total cells that ﬂuoresced (N = 2). All three α-synuclein variants aggregated in a
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Figure 5: E46K α-synuclein expression in budding and ﬁssion yeasts. (a) Western blot of α-synuclein in budding yeast lysates of BY4741
(left) and BY4743 (right) at 24 and 48 hours of expression. E46K expression is similar to WT in BY4741 or lesser in BY4743. (b) Western
blot of α-synuclein in ﬁssion yeast lysates of TCP1 (left)a n dS P 3( right) at 24 and 48 hours of expression. E46K expression is more than WT
in TCP1 (24hrs) and SP3 (24 and 48hrs). (c) Western blot of budding yeast (BY4741) and ﬁssion yeast (TCP1 and SP3) expressing WT and
E46K for 24 hours, probed with serine-129 phosphorylation-speciﬁc antibody (ab59264; Abcam), V5 antibody (for total α-synuclein), and
β-actin (protein loading control). WT and E46K are phosphorylated at serine-129 in both yeasts.
ar e l i a b l ed i ﬀerence in colony number between cells that
contained parent vector and cells expressing WT or E46K α-
synuclein (data not shown).
IntheSP3strain,whereE46Kwasshowntobemoretoxic
than WT α-synuclein, E46K α-synuclein expressing cells
formed even smaller colonies than WT α-synuclein express-
ing cells when α-synuclein was still being expressed (induc-
tion—Figure 6(c)). Unlike in TCP1, these E46K colonies did
not reach the colony size of parent vector cells even after
three days of addition growth even though WT colonies
did (Figure 6(c)). Once again, we did not observe a reliable
diﬀerence in colony number between cells that contained
parent vector and expressing WT or E46K α-synuclein (data
not shown).
In BY4741 budding yeast, similar survival assays did not
demonstrateanydiﬀerenceincolonysizeornumberbetween
parent vector, WT, and E46K expressing cells under induced
conditions at either two or ﬁve days of growth (Figure 6(d)
and data not shown). The initial diﬀerence in colony size
of all yeast cells between repressed (glucose) and induced
(galactose) plates was simply due to the slight general lag in
yeast growth in galactose compared to glucose.
Thus,theWTandE46Kα-synucleintoxicityinTCP1and
the additional E46K selective toxicity in SP3 both correlated
well with reduced yeast growth but not colony number.
3. Discussion
E46K is the most recently discovered of the three α-synuclein
point mutants that cause familial PD. Since its discovery
in 2004, only a handful of mostly in vitro studies have
evaluated E46K’s properties. Using our budding and ﬁssion
yeast PD models, we demonstrate signiﬁcant organismal
evidence that may help explain its toxic potential in PD, and
we discuss three notable ﬁndings below. (1) E46K extensively
associates with membrane systems in both yeasts but does so
in distinct ways: binding plasma membrane in budding yeast
and endomembranes in ﬁssion yeast. (2) E46K aggregates
in ﬁssion yeast, but not in budding yeast, in a time- and
concentration-dependentmanner.(3)E46Kistoxictoﬁssion8 ISRN Neurology
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(a) Survival assay experimental design
Early log phase cells (8hr)
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E46K
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Late log phase cells (18hr)
(b) TCP1
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WT
E46K
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(c) SP3
Vector
WT
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Repression Induction +3days Repression Induction +3days
Early log phase cells (8hr) Late log phase cells (18hr)
(d) BY4741
Figure 6:ImpairedgrowthandsurvivalofﬁssionyeastexpressingE46Kα-synuclein.(a)Survivalassayschematic:1000yeastcellsexpressing
WT or E46K α-synuclein or vector alone were ﬁrst grown in inducing media (without thiamine for ﬁssion yeast and galactose for budding
yeast) for 8 hours (early log phase) or 18 hours (late log phase) and then plated onto repressing (+thiamine for ﬁssion yeast and glucose
for budding yeast) or inducing (−thiamine or galactose). Images of plates were taken either two or ﬁve days of growth and yeast colonies
were examined for size and number (N = 3). (b) Composite images of portions of representative plates that contain TCP1 cells grown in
repressed conditions for two days or induced conditions for two or ﬁve days. (c and d) Same as B, but for SP3 and BY4741 cells, respectively.
After two or ﬁve total days of continuous expression, E46K α-synuclein cells remain signiﬁcantly smaller than WT in SP3 cells, but not in
TCP1 cells or BY4741 cells.ISRN Neurology 9
yeast in a strain-speciﬁc manner that correlates with reduced
cellular growth, survival, and modest accumulation.
3.1. E46K Extensively Associates with Membrane Phospho-
lipids. Insupportofourhypothesis,livecellGFPmicroscopy
illustrates that E46K associates with the plasma membrane
of budding yeast. Surprisingly, no plasma membrane asso-
ciation is observed in ﬁssion yeast. Instead, in one strain
E46K interacts extensively with the cell’s endomembrane
system. Thus, this study is the ﬁrst to demonstrate E46K
association with diverse membrane compartments in living
cells, supporting its well-documented aﬃnity for membrane
phospholipids in vitro. Since E46K binds liposomes more
readily than WT, A30P, or A53T [29], and solution NMR
work also suggests that E46K adopts a structure that favors
lipid binding more rapidly than these other α-synuclein vari-
ants [29, 37], these studies provide a molecular explanation
for why E46K (more than WT or A53T) strongly associates
with endomembrane systems in yeasts. E46K is clearly
diﬀerent from the A30P mutant, which does not associate
with membranes within either yeast this study; [45, 46]n o r
bind lipids in vitro [14, 51–53]. Since E46K enhances N- to
C-terminal contacts within α-synuclein domains [32] and is
within the N-terminal KTKEGV amino acid repeats essential
for membrane association [10, 30, 54], our data strengthens
the notion that the E46K impact on the N to C-terminal
contactlikelyfacilitatesahelicalconformation,thestructural
form required for α-synuclein to interact with lipids [18, 55].
α-Synuclein’s interactions with membrane systems in
cells are well documented. In addition to cytoplasmic
localization in neuronal tissue, α-synuclein also associates
with the secretory pathway [56, 57], localizes to the plasma
membrane [16, 58–62], and outside cells [61–65]. Thus,
E46K’s association (and to a lesser degree, WT and A53T)
with internal membrane systems in ﬁssion yeast cells is
noteworthy. The ﬁssion yeast’s cortical ER surrounds the
nucleus [66]. Thus, E46K α-synuclein’s prominent presence
in perinuclear compartments suggests that it may associate
with ER and disrupt ER to Golgi transport to generate
toxicity,justasWTandA53Tα-synucleinhavebeenreported
to do in budding yeast cells [26, 27] In budding yeast, over-
expression of the secretory pathway speciﬁc G protein Rab1
also rescues yeasts from α-synuclein-dependent [26, 27].
While we do not know why E46K (and to a lesser extent,
WT and A53T) binds such distinct membrane compart-
ments between the two yeasts, diﬀerences in α-synuclein
concentration in the two yeasts are unlikely to be a major
reason, since E46K never associates signiﬁcantly with the
ﬁssion yeast plasma membrane even when expressed at low
concentrations. Since the two yeast species are separated by
almost 400 million years of evolution, inevitable diﬀerences
in plasma membrane and endomembrane composition are a
more likely explanation [67]. We speculatethat diﬀerences in
the plasma and endomembrane composition exist between
budding yeast and ﬁssion yeast and that E46K α-synuclein
might have increased aﬃnity for plasma membrane phos-
pholipids in budding yeast and endomembranes in ﬁssion
yeast. Budding and ﬁssion yeasts do have modest diﬀerences:
in phospholipid composition [68], in ﬁssion yeast being an
inositol auxotroph [69], and ﬁssion yeast’s lipid composition
varieswithtemperatureandgrowth [70].Speciﬁcdiﬀerences
between the yeasts may also exist in the composition of
membraneproteinswithwhichα-synucleinvariantsinteract.
3.2. E46K Aggregates in Fission Yeast. E46K aggregates more
rapidly than WT α-synuclein in ﬁssion yeast, again support-
ing our hypothesis. That this, E46K aggregation more closely
matches A53T α-synuclein is supported by in vitro evidence
that E46K and A53T aggregate at similar rates [29, 30]
In cell culture, E46K readily forms intracellular aggregates
[31]. Our work supports the notion that E46K enhances
α-synuclein aggregation due to its location within the N-
terminalKTKEGVrepeats,whichinﬂuenceaggregationrates
[71]. Synthetic E(XX)K mutations at these points decreased
ﬁbrillization lag time in vitro [71]. Rospigliosi et al. also
demonstrated that the E46K mutant resulted in N to NAC
regioncontact,which,compoundedbyanoveralldecreasein
negativecharge,ishypothesizedtoincreaseaggregationrates,
providing an explanation for E46K’s impact on aggregation
[32].
The absence of E46K aggregation in budding yeast may
beduetotwofactors:themoderateexpressionofα-synuclein
in our lab and the membrane composition diﬀerences
between the two yeasts. In budding and ﬁssion yeasts,
aggregation of α-synuclein increases as its concentration is
increased [21, 46]. Other labs that express α-synuclein at
moderate levels also report plasma membrane association
[42, 44].
3.3. E46K Is Selectively Toxic. E46K’s enhanced toxicity in
ﬁssion yeast supports our hypothesis that it is more toxic
than WT α-synuclein even though neither of them is toxic
in budding yeast. The lack of α-synuclein toxicity in budding
yeast strain BY4741 could be due to dosage-dependent and
strain-speciﬁc toxicity, as α-synuclein is toxic in the W303
strain with two copies expressed but not with one copy
[21]. Our ﬁssion yeast data indicates that endomembrane
association is a key contributor to toxicity although we do
not exclude toxicity contributions from interactions with
the plasma membrane or cytoplasmic aggregation. One of
the most important questions in PD is the identiﬁcation of
the toxic α-synuclein species, and protoﬁbrils possess several
features in vitro that make them excellent candidates for
being this toxic species, including the ability to permeabilize
synthetic vesicles [72]. Both A30P and A53T form more
protoﬁbrilsthanWTα-synucleininvitro[4,11,73],butlittle
still is known whether E46K does the same, in vitro or in
organisms. We speculate that the diﬀerential toxicity (even
within ﬁssion yeast strains) may be due to how much E46K
α-synuclein protoﬁbrils form within each strain and that
endomembrane association may be a signiﬁcant contributor.
The degree and range of E46K association with
endomembrane systems may determine how much it con-
tributes to cytotoxicity. Even though E46K localizes more
to internal organelles in TCP1 than WT α-synuclein does,
their level of toxicity is similar. We speculate that the added
toxicity in SP3 may partly be due to more E46K localization
to vacuoles/prevacuoles. Thus, disruption of vesicle integrity10 ISRN Neurology
may mediate toxicity as much as added association with the
ER. Strain diﬀerences in lipid composition may also underlie
why SP3 diﬀers from TCP1 in the extent of α-synuclein
association with intracellular organelles. Since most TCP1
cells express E46K in aggregates, the few cells that do exhibit
endomembrane localization likely produce too little toxicity
to be detected by the growth and survival assays. Lastly, the
diﬀerence in toxicity could be due to the h− (TCP1) and h+
(SP3) mating-type diﬀerences, including altered interactions
of α-synuclein with secretion of speciﬁc mating factors.
Our data conﬁrms an initial report in budding yeast [74]
and extends it to ﬁssion yeast that yeasts possess protein
kinases that can phosphorylate human α-synuclein. We are
also the ﬁrst to report that WT and E46K α-synuclein
are phosphorylated in a ﬁssion yeast model (for fuller
description, see [75]). Although the extent of serine-129
phosphorylation does not correlate with enhanced E46K α-
synuclein toxicity in ﬁssion yeast, it provided us the oppor-
tunity to investigate the contribution of phosphorylation to
α-synuclein aggregation and membrane association in both
models that we report elsewhere.
Future studies in ﬁssion yeast will determine whether
α-synuclein will disrupt vesicular pool distribution, accu-
mulates in vesicles, and colocalizes with secretory pathway
proteins, as it does in budding yeast [21, 27, 76]. It is
possible that such α-synuclein endomembrane association
also impairs α-synuclein degradation and toxicity via lysos-
mal pathways, as has been observed in budding yeast ([47,
77], Perez et al. (manuscript submitted), Konnikova et al.
(manuscript in prep)), mammalian cells [78–82]a n dw o r m s
[83].
4. Conclusion
Both yeast models recapitulate and extend our in vitro and
cell culture knowledge of E46K α-synuclein familial mutant
properties in two organismal model systems. Together, they
illustrate that E46K can both aggregate within cells and
associate with its diverse membrane systems. Importantly,
the organismal context regulates both these features by vary-
ing the extent of aggregation and the extent of association
with plasma membrane and endomembrane systems. Our
data indicates that α-synuclein binding to endomembranes
may be key to generating toxicity that negatively impacts
cellular growth and survival. Finally, our work further
strengthens the relevance of ﬁssion yeast, alongside the
more widely accepted budding yeast, to serve as a model
organism for studying misfolded proteins linked to human
neurodegeneration, opening doors for genetic screens and
chemical treatments to dissect the role of genetic factors that
regulate α-synuclein misfolding and toxicity and contribute
to deeper understanding of PD pathogenesis.
5.MaterialsandMethods
5.1. α-Synuclein Constructs. cDNAs of wild-type (WT) and
A53T α-synuclein were provided by Christopher Ross at
Johns Hopkins University. These α-synuclein cDNAs were
ﬁrst subcloned into the mammalian expression vector
pcDNA3.1/C-terminal GFP (Invitrogen), fusing α-synuclein
with GFP at the C-terminus. The α-Synuclein-GFP cDNAs
andGFPcDNAwerethenPCR-ampliﬁedandsubclonedinto
the pYES2.1/V5-His-TOPO budding yeast expression vector
(Invitrogen) or pNMT1/V5-His-TOPO ﬁssion yeast vector
(Invitrogen). The α-synuclein-GFP fusion yeast vectors were
transformed into chemically competent E. coli cells for
replication and storage. The A30P mutant was created using
site-directed mutagenesis (Invitrogen) on WT α-synuclein-
GFP pYES2.1/V5-His-TOPO budding yeast expression vec-
tor (Invitrogen) or pNMT1/V5-His-TOPO as described in
Sharma et al. and Brandis et al., respectively [45, 46]. The
E46K mutant was made similarly created with the following
primers:
E46K FP: 5  ATGTAGGCTCCAAAAACAAGAAGG-
GAGTGGTGC 3 
E46K RP: 5  CTTGGTTTTGGAGCCTACATAGAG-
AACACC 3 
Mutations were sequenced at University of Chicago to con-
ﬁrm successful substitution. The parent pYES2.1 vector for
budding yeast (Invitrogen) and parent pNMT1 pREP vector
(gift from Judy Potashkin, Rosalind Franklin University, Ill,
USA) served as controls.
5.2. Yeast Strains. Parent budding yeast strains BY4741
(MATa his3Δ1l e u 2 Δ0m e t 1 5 Δ0u r a 3 Δ0), BY4742 (MATα
his3Δ1l e u 2 Δ0l y s 2 Δ0m e t 1 5 Δ0u r a 3 Δ0), and BY4743
(MATa/α his3Δ1l e u 2 Δ0l y s 2 Δ0u r a 3 Δ0). Fission yeast strains
TCP1 (h− leu1-32) and SP3 (h+ leu1-32)w e r ep r o v i d e db y
Invitrogen and Judy Potashkin (Rosalind Franklin University
of Medicine and Science, North Chicago, Ill, USA), respec-
tively.
5.3. S. cerevisiae α-Synuclein Expression. α-Synuclein expres-
sion plasmid vectors were transformed into yeast strains
as described [84]. For selection, yeast cells were grown on
synthetic-complete media lacking uracil (SC-Ura). In the
pYES2vector,α-synucleinexpressionwascontrolledthrough
a tightly regulated galactose-inducible promoter (Gal1).
Yeast were grown to mid-log phase in SC-Ura glucose (2%)
or SC-Ura raﬃnose (2%) media at 30◦C. Cells were washed
with water and diluted to log-phase (5×106 cells/mL) in SC-
Ura galactose (2%) media to induce α-synuclein expression.
5.4. S. pombe α-Synuclein Expression. S. pombe strains were
transformed with pNMT1 vectors using the lithium-acetate
transformationmethod[85].Transformedcellswereselected
by growth on pombe dropout medium-leucine (PDM-Leu)
containing 10μM thiamine. α-Synuclein was expressed by
growth in thiamine-lacking media as described in [46].
5.5. Western Analysis. Budding or ﬁssion yeast cells at
2.5 × 107 cells/mL concentration were washed twice with
100mM NaN3 and solubilized in electrophoresis sample
buﬀer (ESB) [84]. The ESB contained 2% sodium dodecyl
sulfate (SDS), 80mM Tris (Ph 6.8), 10% glycerol, 1.5%
dithiothreitol, 1mg/mL bromophenol blue, and a cocktailISRN Neurology 11
of protease inhibitors and solubilizing agents (1% Triton-
X 100, 1mM phenylmethylsulfonyl ﬂuoride, 1mM benza-
midine, 1mM sodium orthovanadate, 0.7mg/mL pepstatin
A, 0.5mg/mL leupeptin, 10mg/mL E64, 2mg/mL aprotinin,
and 2mg/mL chymostatin). Lysates were electrophoresed
at 130 volts on a 10%–20% Tris-Glycine gel (Invitrogen)
with 1X SDS running buﬀer. SeeBlue (Invitrogen) molecular
ladder was used as a standard. Gels were transferred to
PVDF membranes using a semidry transfer method and
probed using the desired antibodies. To detect α-synuclein,
a mouse monoclonal anti-V5-AP antibody (Invitrogen) was
used at 1:2000. Mouse antiphosphoglycerokinase (PGK;
Molecular probes) was used at 1:1000 as a loading control
for budding yeast and anti-β-actin (Abcam) was used at
1:1000 as a loading control for ﬁssion yeast. For both,
goat antimouse secondary antibody (Invitrogen) was used.
Serine-129 phosphorylation blots were probed with a rabbit
α-synuclein (phospho S129) antibody (ab59264; Abcam) at
1:500, followed by a goat antirabbit secondary antibody
(Santa Cruz Biotechnology). All blots were visualized by
detecting for alkaline-phosphatase activity. All blots were
done at least three times.
5.6. OD600 Growth Curve Analysis. Yeast cells were grown
in either 10mL SC-Ura+glucose (budding yeast) or EMM+T
(ﬁssionyeast)overnightat30◦Cand200rpm.Tocollectcells,
yeast were pelleted at 1500 × gf o r5m i n u t e sa t4 ◦C. They
were washed twice with 5mL H2O, re-suspended in 10mL
H2O, and counted using a hemocytometer to determine cell
density.Flaskscontaining25mLSC-Ura+galactose(budding
yeast)orEMM−T(ﬁssionyeast)wereinoculatedtoadensity
of 2.0 × 106 cells/mL. Duplicate spectrophotometer 600nm
absorbance measurements of 1mL of cells in a plastic cuvette
were taken at 0, 3, 6, 12, 18, 24, 36, and 48 hours after-
induction. The spectrophotometer model was a Hitachi U-
2000 Spectrophotometer. A growth curve was generated by
plotting the average absorbance readings of three separate
experimentsversustimeinMicrosoftExcel.Astudent’st-test
was used to determine signiﬁcance.
5.7. Serial Dilution Spotting. Yeast cells were grown in either
10mL SC-Ura+glucose (budding yeast) or EMM+T (ﬁssion
yeast) overnight at 30◦C and 200rpm. To collect cells, yeast
were pelleted at 1500 × gf o r5m i n u t e sa t4 ◦C. They
were washed twice with 5mL H2O, resuspended in 10mL
H2O, and counted using a hemocytometer to determine cell
density. 2.0×106 cellswereremoved and pelleted. The super-
natant was removed, and cells were resuspended in 1mL
H2O. Cells were diluted 5 fold in a 96 well microtitier plate
and spotted onto SC-Ura+glucose and Sc-Ura+galactose
(budding yeast) or EMM+T and EMM−T (ﬁssion yeast)
growth plates. Cells were grown for 24 hours, and pictures
were taken using an HP Canoscan scanner. Images were
imported into Adobe Photoshop CS2. All spotting experi-
ments were conducted at least three times in triplicate.
5.8. GFP Microscopy. Yeast cells were grown in either 10mL
SC-Ura+glucose (budding yeast) or EMM+T (ﬁssion yeast)
overnight at 30◦C and 200rpm. To collect cells, yeast were
pelleted at 1500 × gf o r5m i n u t e sa t4 ◦C. They were
washed twice with 5mL H2O, resuspended in 10 mL H2O,
and counted using a hemocytometer to determine cell
density.Flaskscontaining25mLSC-Ura+galactose(budding
yeast) or EMM−T (ﬁssion yeast) were inoculated to a
density of 2.0 × 107 cells/mL. 1mL of cell culture was
pelleted at 5000rpm for 1 minute. 900uL of supernatant
was removed. The remaining 100uL of cell culture was
vortexed, and 5–10uL of sample was pipetted onto a
glass slide. Cells were visualized using a Nikon TE2000-
U ﬂuorescent microscope, and images were collected and
quantiﬁed using Metamorph 4.0 software. All microscopy
experiments were conducted twice. For each yeast sample,
at each time point ∼7 5 0c e l l so fe a c ht y p ew e r es c o r e df o r
all or some of these localization patterns (depending on the
yeast): cytoplasmically diﬀuse, plasma membrane, aggregate,
membrane/diﬀuse, membrane/aggregate, endomembrane,
endomembrane/aggregate, and endomembrane/diﬀuse (bot-
tom). All microscopy experiments were conducted twice.
DAPI staining was performed as described [85].
5.9. Survival Assay. Yeast cells were grown in either 10mL
SC-Ura+glucose (budding yeast) or EMM+T (ﬁssion yeast)
overnight at 30◦C and 200rpm. To collect cells, yeast were
pelleted at 1500 × gf o r5m i n u t e sa t4 ◦C. They were washed
three times with 5mL H2O, resuspended in 10 mL H2O, and
counted using a hemocytometer to determine cell density.
Flasks containing 25mL SC-Ura+galactose (budding yeast)
or EMM−T (ﬁssion yeast) were inoculated to a density of
2.0×107 cells. At 8 and 18 hours after induction, cell density
was determined. 1.8 × 106 cells were removed and washed
once with 1mL of H2O. The cells were resuspended in
1mL of water, and diluted 1:1000. 300μL of 1:1000 diluted
cells (550 cells) were spread on 150mm plates containing
SC-Ura+Galactose and SC-Ura+Glucose (budding yeast) or
EMM−T and EMM+T (ﬁssion yeast), for either two days or
threeadditionaldaysat30◦C,andimagesweretakenofplates
a n da n a l y z e df o rc o l o n yn u m b e ra n ds i z e .A l ls u r v i v a la s s a y s
were conducted at least three times in triplicate.
Acknowledgments
The authors declare they have no conﬂict of interests. M.
Fiske, M. White, S. Valtierra, S. Herrera, K. Solvang, and
A. Konnikova performed experiments. M. Fiske, M. White,
and S. DebBurman wrote the paper. M. Fiske, M. White,
and S. DebBurman conceived and designed experiments.
At Lake Forest College, the authors thank Pliny Smith and
Beth Herbert and the following undergraduates (Katrina
Brandis, Michael Zorniak, Lokesh Kukreja, Alexandra Ayala,
Ray Choi, Jaime Perez, Daniel Sanchez, Kayla Ahlstrand,
PeterSullivan,MadhaviSenagolage,andNatalieKukulka)for
editorial comments. S. DebBurman was supported by grants
from NIH (R15 Grant no. NS048508-01 and NS048508-02)
and NSF (CCLI 0310627 and MRI 0115919). K. Solvang
was supported by an NIH ARRA summer undergraduate
research supplement. S. Herrera was supported by an NIH-
NINDS diversity supplement undergraduate research grant.
M. Fiske was supported by a Parkinson Disease Foundation12 ISRN Neurology
summer undergraduate research fellowship. M. Fiske and M.
White are Co-ﬁrst authors.
References
[1] C. W. Olanow and W. G. Tatton, “Etiology and pathogenesis
of Parkinson’s disease,” Annual Review of Neuroscience, vol. 22,
pp. 123–144, 1999.
[2] M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa,
a n dM .G o e d e r t ,“ α-synuclein in ﬁlamentous inclusions of
LewybodiesfromParkinson’sdiseaseanddementiawithLewy
bodies,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 95, no. 11, pp. 6469–6473, 1998.
[3] T. M. Dawson and V. L. Dawson, “Molecular pathways of
neurodegeneration in Parkinson’s disease,” Science, vol. 302,
no. 5646, pp. 819–822, 2003.
[ 4 ]M .S .G o l d b e r ga n dP .T .L a n s b u r yJ r . ,“ I st h e r eac a u s e -
and-eﬀect relationship between α-synuclein ﬁbrillization and
Parkinson’s disease?” Nature Cell Biology,v o l .2 ,n o .7 ,p p .
E115–E119, 2000.
[5] K. Ono, M. Hirohata, and M. Yamada, “α-synuclein assembly
as a therapeutic target of Parkinson’s disease and related
disorders,” Current Pharmaceutical Design, vol. 14, no. 30, pp.
3247–3266, 2008.
[6] K. Vekrellis, M. Xilouri, E. Emmanouilidou, and L. Stefanis,
“Inducible over-expression of wild type α-synuclein in human
neuronal cells leads to caspase-dependent non-apoptotic
death,” Journal of Neurochemistry, vol. 109, no. 5, pp. 1348–
1362, 2009.
[7] C. Schiesling, N. Kieper, K. Seidel, and R. Kr¨ uger, “Review:
familial Parkinson’s disease—genetics, clinical phenotype and
neuropathology in relation to the common sporadic form of
thedisease,”NeuropathologyandAppliedNeurobiology,vol.34,
no. 3, pp. 255–271, 2008.
[8] M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation
in the α-synuclein gene identiﬁed in families with Parkinson’s
disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997.
[9] R. Kr¨ uger, W. Kuhn, T. M¨ uller et al., “Ala30Pro mutation in
the gene encoding α-synuclein in Parkinson’s disease,” Nature
Genetics, vol. 18, no. 2, pp. 106–108, 1998.
[10] J. J. Zarranz, J. Alegre, J. C. G´ omez-Esteban et al., “The new
m u t a t i o n ,E 4 6 K ,o fα-synuclein causes Parkinson and Lewy
body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–
173, 2004.
[11] K. A. Conway, J. D. Harper, and P. T. Lansbury, “Accelerated in
vitro ﬁbril formation by a mutant α-synuclein linked to early-
onset Parkinson disease,” Nature Medicine, vol. 4, no. 11, pp.
1318–1320, 1998.
[ 1 2 ]B .I .G i a s s o n ,K .U r y u ,J .Q .T r o j a n o w s k i ,a n dV .M .Y .
Lee, “Mutant and wild type human α-synucleins assemble
into elongated ﬁlaments with distinct morphologies in vitro,”
Journal of Biological Chemistry, vol. 274, no. 12, pp. 7619–
7622, 1999.
[13] K. A. Conway, J. D. Harper, and P. T. Lansbury Jr., “Fibrils
formed in vitro from α-synuclein and two mutant forms
linked to Parkinson’s disease are typical amyloid,” Biochem-
istry, vol. 39, no. 10, pp. 2552–2563, 2000.
[ 1 4 ]P .H .J e n s e n ,M .S .N i e l s e n ,R .J a k e s ,C .G .D o t t i ,a n dM .
Goedert, “Binding of α-synuclein to brain vesicles is abolished
by familial Parkinson’s disease mutation,” Journal of Biological
Chemistry, vol. 273, no. 41, pp. 26292–26294, 1998.
[ 1 5 ]D .D .M u r p h y ,S .M .R u e t e r ,J .Q .T r o j a n o w s k i ,a n dV .M .Y .
Lee, “Synucleins are developmentally expressed, and α-synu-
clein regulates the size of the presynaptic vesicular pool in
primary hippocampal neurons,” Journal of Neuroscience, vol.
20, no. 9, pp. 3214–3220, 2000.
[16] J. M. George, H. Jin, W. S. Woods, and D. F. Clayton,
“Characterization of a novel protein regulated during the
critical period for song learning in the zebra ﬁnch,” Neuron,
vol. 15, no. 2, pp. 361–372, 1995.
[17] A. Abeliovich, Y. Schmitz, I. Fari˜ nas et al., “Mice lacking
α-synuclein display functional deﬁcits in the nigrostriatal
dopamine system,” Neuron, vol. 25, no. 1, pp. 239–252, 2000.
[ 1 8 ]W .S .D a v i d s o n ,A .J o n a s ,D .F .C l a y t o n ,a n dJ .M .G e o r g e ,
“Stabilization of α-synuclein secondary structure upon bind-
ing to synthetic membranes,” Journal of Biological Chemistry,
vol. 273, no. 16, pp. 9443–9449, 1998.
[ 1 9 ]R .S h a r o n ,M .S .G o l d b e r g ,I .B a r - J o s e f ,R .A .B e t e n s k y ,J .
S h e n ,a n dD .J .S e l k o e ,“ α-synuclein occurs in lipid-rich high
molecular weight complexes, binds fatty acids, and shows
homology to the fatty acid-binding proteins,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 98, no. 16, pp. 9110–9115, 2001.
[20] D. Eliezer, E. Kutluay, R. Bussell, and G. Browne, “Conforma-
tional properties of α-synuclein in its free and lipid-associated
states,” Journal of Molecular Biology, vol. 307, no. 4, pp. 1061–
1073, 2001.
[21] T. F. Outeiro and S. Lindquist, “Yeast cells provide insight into
alpha-synuclein biology and pathobiology,” Science, vol. 302,
no. 5651, pp. 1772–1775, 2003.
[22] M. A. Alim, Q.-L. Ma, K. Takeda et al., “Demonstration of
a role for α-synuclein as a functional microtubule-associated
protein,” Journal of Alzheimer’s Disease, vol. 6, no. 4, pp. 435–
442, 2004.
[23] J. M. Jenco, A. Rawlingson, B. Daniels, and A. J. Morris,
“RegulationofphospholipaseD2:selectiveinhibitionofmam-
malian phospholipase D isoenzymes by α-a n dβ-synucleins,”
Biochemistry, vol. 37, no. 14, pp. 4901–4909, 1998.
[24] N.Ostrerova,L.Petrucelli,M.Farreretal.,“α-synucleinshares
physical and functional homology with 14-3-3 proteins,”
Journal of Neuroscience, vol. 19, no. 14, pp. 5782–5791, 1999.
[25] S. Engelender, Z. Kaminsky, G. Xin et al., “Synphilin-1
associates with α-synuclein and promotes the formation of
cytosolic inclusions,” Nature Genetics, vol. 22, no. 1, pp. 110–
114, 1999.
[26] A. A. Cooper, A. D. Gitler, A. Cashikar et al., “α-synuclein
blocks ER-Golgi traﬃc and Rab1 rescues neuron loss in
Parkinson’s models,” Science, vol. 313, no. 5785, pp. 324–328,
2006.
[27] A. D. Gitler, B. J. Bevis, J. Shorter et al., “The Parkinson’s
diseaseproteinα-synucleindisruptscellularRabhomeostasis,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 105, no. 1, pp. 145–150, 2008.
[28] B. Caughey and P. T. Lansbury, “Protoﬁbrils, pores, ﬁbrils,
and neurodegeneration: separating the responsible protein
aggregates from the innocent bystanders,” Annual Review of
Neuroscience, vol. 26, pp. 267–298, 2003.
[29] W. Choi, S. Zibaee, R. Jakes et al., “Mutation E46K increases
phospholipid binding and assembly into ﬁlaments of human
α-synuclein,” FEBS Letters, vol. 576, no. 3, pp. 363–368, 2004.
[30] E. A. Greenbaum, C. L. Graves, A. J. Mishizen-Eberz et al.,
“The E46K mutation in α-synuclein increases amyloid ﬁbril
formation,” Journal of Biological Chemistry, vol. 280, no. 9, pp.
7800–7807, 2005.
[31] N. Pandey, R. E. Schmidt, and J. E. Galvin, “The alpha-
synuclein mutation E46K promotes aggregation in cultured
cells,” Experimental Neurology, vol. 197, no. 2, pp. 515–520,
2006.ISRN Neurology 13
[32] C. C. Rospigliosi, S. McClendon, A. W. Schmid et al.,
“E46K Parkinson’s-linked mutation enhances C-terminal-to-
N-terminal contacts in α-synuclein,” J o u r n a lo fM o l e c u l a r
Biology, vol. 388, no. 5, pp. 1022–1032, 2009.
[33] P. T. Lansbury, “Evolution of amyloid: what normal protein
folding may tell us about ﬁbrillogenesis and disease,” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 96, no. 7, pp. 3342–3344, 1999.
[34] R. A. Fredenburg, C. Rospigliosi, R. K. Meray et al., “The
impact of the E46K mutation on the properties of α-synuclein
in its monomelic and oligomeric states,” Biochemistry, vol. 46,
no. 24, pp. 7107–7118, 2007.
[35] E. Di Pasquale, J. Fantini, H. Chahinian, M. Maresca, N.
Ta¨ ıeb, and N. Yahi, “Altered Ion channel formation by the
Parkinson’s-disease-linked E46K mutant of α-synuclein is
corrected by GM3 but not by GM1 gangliosides,” Journal of
Molecular Biology, vol. 397, no. 1, pp. 202–218, 2010.
[36] M. St¨ ockl, P. Fischer, E. Wanker, and A. Herrmann, “α-
synuclein selectively binds to anionic phospholipids embed-
ded in liquid-disordered domains,” Journal of Molecular
Biology, vol. 375, no. 5, pp. 1394–1404, 2008.
[37] C. R. Bodner, A. S. Maltsev, C. M. Dobson, and A. Bax,
“Diﬀerential phospholipid binding of α-synuclein variants
implicated in Parkinson’s disease revealed by solution NMR
spectroscopy,” Biochemistry, vol. 49, no. 5, pp. 862–871, 2010.
[38] A.Klegeris,S.Pelech,B.I.Giassonetal.,“α-synucleinactivates
stress signaling protein kinases in THP-1 cells and microglia,”
Neurobiology of Aging, vol. 29, no. 5, pp. 739–752, 2008.
[39] C. B. Kunst, E. Mezey, M. J. Brownstein, and D. Patterson,
“Mutations in SOD1 associated with amyotrophic lateral
sclerosis cause novel protein interactions,” Nature Genetics,
vol. 15, no. 1, pp. 91–94, 1997.
[40] J. Ma and S. Lindquist, “De novo generation of a PrP-like
conformation in living cells,” Nature Cell Biology, vol. 1, no.
6, pp. 358–361, 1999.
[41] S. Krobitsch and S. Lindquist, “Aggregation of huntingtin in
yeast varies with the length of the polyglutamine expansion
and the expression of chaperone proteins,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 97, no. 4, pp. 1589–1594, 2000.
[42] P. J. Muchowski, K. Ning, C. D’Souza-Schorey, and S.
Fields, “Requirement of an intact microtubule cytoskeleton
for aggregation and inclusion body formation by a mutant
huntingtin fragment,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 99, no. 2, pp. 727–
732, 2002.
[43] P.Zabrocki,K.Pellens,T.Vanhelmontetal.,“Characterization
of α-synuclein aggregation and synergistic toxicity with pro-
t e i nt a ui ny e a s t , ”FEBS Journal, vol. 272, no. 6, pp. 1386–1400,
2005.
[44] C. Dixon, N. Mathias, R. M. Zweig, D. A. Davis, and D.
S. Gross, “α-synuclein targets the plasma membrane via the
secretory pathway and induces toxicity in yeast,” Genetics, vol.
170, no. 1, pp. 47–59, 2005.
[45] N. Sharma, K. A. Brandis, S. K. Herrera et al., “α-synuclein
budding yeast model: toxicity enhanced by impaired protea-
some and oxidative stress,” Journal of Molecular Neuroscience,
vol. 28, no. 2, pp. 161–178, 2006.
[46] K. A. Brandis, I. F. Holmes, S. J. England, N. Sharma, L. Kuk-
reja, and S. K. DebBurman, “α-synuclein ﬁssion yeast model:
concentration-dependent aggregation without plasma mem-
brane localization or toxicity,” Journal of Molecular Neuro-
science, vol. 28, no. 2, pp. 179–192, 2006.
[47] S. Willingham, T. F. Outeiro, M. J. DeVit, S. L. Lindquist, and
P. J. Muchowski, “Yeast genes that enhance the toxicity of a
mutant huntingtin fragment or α-synuclein,” Science, vol. 302,
no. 5651, pp. 1769–1772, 2003.
[48] M. Okochi, J. Walter, A. Koyama et al., “Constitutive phos-
phorylation of the Parkinson’s disease associated α-synuclein,”
Journal of Biological Chemistry, vol. 275, no. 1, pp. 390–397,
2000.
[49] H. Fujiwara, M. Hasegawa, N. Dohmae et al., “α-synuclein
is phosphorylated in synucleinopathy lesions,” Nature Cell
Biology, vol. 4, no. 2, pp. 160–164, 2002.
[50] K. E. Paleologou, A. Oueslati, G. Shakked et al., “Phospho-
rylationatS87isenhancedinsynucleinopathies,inhibitsα-sy-
nuclein oligomerization, and inﬂuences synuclein-membrane
interactions,” Journal of Neuroscience, vol. 30, no. 9, pp. 3184–
3198, 2010.
[ 5 1 ]O .M .A .E l - A g n a f ,R .J a k e s ,M .D .C u r r a ne ta l . ,“ A g g r e g a t e s
from mutant and wild-type α-synuclein proteins and NAC
peptide induce apoptotic cell death in human neuroblastoma
cells by formation of β-sheet and amyloid-like ﬁlaments,”
FEBS Letters, vol. 440, no. 1-2, pp. 71–75, 1998.
[52] R. Bussell and D. Eliezer, “Eﬀects of Parkinson’s disease-linked
mutations on the structure of lipid-associated α-synuclein,”
Biochemistry, vol. 43, no. 16, pp. 4810–4818, 2004.
[53] T. S. Ulmer and A. Bax, “Comparison of structure and
dynamicsofmicelle-boundhumanα-synucleinandParkinson
disease variants,” Journal of Biological Chemistry, vol. 280, no.
52, pp. 43179–43187, 2005.
[54] R. Jakes, M. G. Spillantini, and M. Goedert, “Identiﬁcation of
two distinct synucleins from human brain,” FEBS Letters, vol.
345, no. 1, pp. 27–32, 1994.
[ 5 5 ]R .J .P e r r i n ,W .S .W o o d s ,D .F .C l a y t o n ,a n dJ .M .G e o r g e ,
“Interaction of human α-synuclein and Parkinson’s disease
variants with phospholipids: structural analysis using site-
directed mutagenesis,” Journal of Biological Chemistry, vol.
275, no. 44, pp. 34393–34398, 2000.
[56] M. M. Tompkins, W. P. Gai, S. Douglas, and S. J. Bunn, “α-
synucleinexpressionlocalizestotheGolgiapparatusinbovine
adrenal medullary chromaﬃnc e l l s , ”Brain Research, vol. 984,
no. 1-2, pp. 233–236, 2003.
[57] H. J. Lee, S. Patel, and S. J. Lee, “Intravesicular localization
and exocytosis of α-synuclein and its aggregates,” Journal of
Neuroscience, vol. 25, no. 25, pp. 6016–6024, 2005.
[58] L. Maroteaux and R. H. Scheller, “The rat brain synucleins;
family of proteins transiently associated with neuronal mem-
brane,”MolecularBrainResearch,vol.11,no.3-4,pp.335–343,
1991.
[59] T. Shibayama-Imazu, I. Okahashi, K. Omata et al., “Cell
and tissue distribution and developmental change of neuron
speciﬁc 14 kDa protein (phosphoneuroprotein 14),” Brain
Research, vol. 622, no. 1-2, pp. 17–25, 1993.
[ 6 0 ]M .C .I r i z a r r y ,W .G r o w d o n ,T .G o m e z - I s l ae ta l . ,“ N i g r a l
and cortical Lewy bodies and dystrophic nigral neurites in
Parkinson’s disease and cortical Lewy body disease contain α-
synuclein immunoreactivity,” Journal of Neuropathology and
Experimental Neurology, vol. 57, no. 4, pp. 334–337, 1998.
[61] P. J. McLean, H. Kawamata, S. Ribich, and B. T. Hyman,
“Membrane association and protein conformation of α-
synuclein in intact neurons. Eﬀect of Parkinson’s disease-
linkedmutations,”JournalofBiologicalChemistry,vol.275,no.
12, pp. 8812–8816, 2000.
[62] P. J. Kahle, M. Neumann, L. Ozmen et al., “Subcellular
localization of wild-type and Parkinson’s disease-associated14 ISRN Neurology
mutant α-synuclein in human and transgenic mouse brain,”
Journal of Neuroscience, vol. 20, no. 17, pp. 6365–6373, 2000.
[63] R. Borghi, R. Marchese, A. Negro et al., “Full length α-
synuclein is present in cerebrospinal ﬂuid from Parkinson’s
diseaseandnormalsubjects,”NeuroscienceLetters,vol.287,no.
1, pp. 65–67, 2000.
[64] P. H. Lee, G. Lee, H. J. Park, O. Y. Bang, I. S. Joo, and
K. Huh, “The plasma alpha-synuclein levels in patients with
Parkinson’s disease and multiple system atrophy,” Journal of
Neural Transmission, vol. 113, no. 10, pp. 1435–1439, 2006.
[65] T.Tokuda,S.A.Salem,D.Allsopetal.,“Decreasedα-synuclein
in cerebrospinal ﬂuid of aged individuals and subjects with
Parkinson’s disease,” Biochemical and Biophysical Research
Communications, vol. 349, no. 1, pp. 162–166, 2006.
[66] A. L. Pidoux and J. Armstrong, “The BiP protein and the
endoplasmic reticulum of Schizosaccharomyces pombe: fate
of the nuclear envelope during cell division,” Journal of Cell
Science, vol. 105, no. 4, pp. 1115–1120, 1993.
[67] A. E. Roux, P. Chartrand, G. Ferbeyre, and L. A. Rokeach,
“Fission yeast and other yeasts as emergent models to unravel
cellularagingineukaryotes,”TheJournalsofGerontologySeries
A, vol. 65, no. 1, pp. 1–8, 2010.
[68] S. Fernandez, M. J. Homann, S. A. Henry, and G. M. Carman,
“Metabolism of the phospholipid precursor inositol and its
relationship to growth and viability in the natural auxotroph
Schizosaccharomycespombe,”JournalofBacteriology,vol.166,
no. 3, pp. 779–786, 1986.
[69] I. McVeigh and E. Bracken, “The nutrition of Schizosaccha-
romyces pombe,” Mycologia, vol. 47, no. 1, pp. 13–25, 1955.
[70] V. M. McDonough and T. M. Roth, “Growth temperature
aﬀects accumulation of exogenous fatty acids and fatty acid
composition in Schizosaccharomyces pombe,” Antonie van
Leeuwenhoek, vol. 86, no. 4, pp. 349–354, 2005.
[71] R. Harada, N. Kobayashi, J. Kim et al., “The eﬀect of amino
acid substitution in the imperfect repeat sequences of α-
s y n u c l e i no nﬁ b r i l l a t i o n , ”Biochimica et Biophysica Acta, vol.
1792, no. 10, pp. 998–1003, 2009.
[72] M. J. Volles and P. T. Lansbury, “Relationships between the
sequence of α-synuclein and its membrane aﬃnity, ﬁbril-
lization propensity, and yeast toxicity,” Journal of Molecular
Biology, vol. 366, no. 5, pp. 1510–1522, 2007.
[73] J. Li, V. N. Uversky, and A. L. Fink, “Eﬀect of familial
Parkinson’s disease point mutations A30P and A53T on the
structural properties, aggregation, and ﬁbrillation of human
α-synuclein,” Biochemistry, vol. 40, no. 38, pp. 11604–11613,
2001.
[74] E. Yeger-Lotem, L. Riva, L. J. Su et al., “Bridging high-
throughput genetic and transcriptional data reveals cellular
responsestoalpha-synucleintoxicity,”Nature Genetics,vol.41,
no. 3, pp. 316–323, 2009.
[75] M. Fiske, S. Valtierra, M. Solvang et al., “Contribution of
alanine-76 and serine phosphorylation in α-synuclein mem-
brane association and aggregation in yeasts,” Parkinson’s Dise-
ase. In press.
[76] J. H. Soper, S. Roy, A. Stieber et al., “α-synuclein-induced
aggregation of cytoplasmic vesicles in Saccharomyces cere-
visiae,” Molecular Biology of the Cell, vol. 19, no. 3, pp. 1093–
1103, 2008.
[77] T. R. Flower, L. S. Chesnokova, C. A. Froelich, C. Dixon,
and S. N. Witt, “Heat shock prevents alpha-synuclein-induced
apoptosis in a yeast model of Parkinson’s disease,” Journal of
Molecular Biology, vol. 351, no. 5, pp. 1081–1100, 2005.
[78] N. Thayanidhi, J. R. Helm, D. C. Nycz, M. Bentley, Y. Liang,
and J. C. Hay, “α-synuclein delays endoplasmic reticulum
(ER)-to-Golgi transport in mammalian cells by antagonizing
ER/Golgi SNAREs,” Molecular Biology of the Cell, vol. 21, no.
11, pp. 1850–1863, 2010.
[79] J. L. Webb, B. Ravikumar, J. Atkins, J. N. Skepper, and D. C.
Rubinsztein, “α-synuclein is degraded by both autophagy and
the proteasome,” Journal of Biological Chemistry, vol. 278, no.
27, pp. 25009–25013, 2003.
[80] A. M. Cuervo, L. Stafanis, R. Fredenburg, P. T. Lansbury, and
D. Sulzer, “Impaired degradation of mutant α-synuclein by
chaperone-mediated autophagy,” Science, vol. 305, no. 5688,
pp. 1292–1295, 2004.
[81] H. J. Lee, F. Khoshaghideh, S. Patel, and S. J. Lee, “Clearance
of α-synuclein oligomeric intermediates via the lysosomal
degradation pathway,” Journal of Neuroscience, vol. 24, no. 8,
pp. 1888–1896, 2004.
[82] J. A. Lee and F. B. Gao, “Roles of ESCRT in autophagy-
associated neurodegeneration,” Autophagy,v o l .4 ,n o .2 ,p p .
230–232, 2008.
[83] T. Kuwahara, A. Koyama, S. Koyama et al., “A systematic RNAi
screen reveals involvement of endocytic pathway in neuronal
dysfunction in α-synuclein transgenic C . elegans,” Human
Molecular Genetics, vol. 17, no. 19, pp. 2997–3009, 2008.
[84] D. Burke, D. Dawson, and T. Stearns, Methods in Yeast
Genetics, Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY, USA, 2000.
[85] C. Alfa, Experiments with Fission Yeast, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY, USA, 1993.